



Media Alert: 18 May 2023 – Melbourne, Australia

[Mind Medicine Australia to Supply Psilocybin and MDMA at No Cost for New Innovative Clinical Trials](#)

[Mind Medicine Australia](#) (MMA) is a registered charity set up to develop the ecosystem in Australia so that psychedelic-assisted therapies can become an available option for patients suffering from key classes of mental illness. Innovation in the sector is desperately needed because current treatments for mental illnesses such as depression and post-traumatic stress disorder don't work or don't work adequately for a large number of people suffering from these conditions.

As a result of MMA lodging evidence-based applications with the TGA and strongly advocating for change with all key stakeholders in Australia, two psychedelic medicines – psilocybin and MDMA - have now been rescheduled by the TGA. This will allow these medicines to be prescribed by authorised psychiatrists from 1 July 2023 for patients suffering from treatment resistant depression (psilocybin) and patients suffering from treatment resistant post-traumatic stress disorder (MDMA). Australia has become the first country in the World to do this.

MMA recently announced an agreement with Canadian end-to-end GMP manufacturer **Optimi Health Corp** for the supply to Australia of GMP medical grade psilocybin and GMP medical grade MDMA for clinical use and use in clinical trials. This agreement will ensure that the medicines are available in Australia from 1 July 2023 at affordable prices to support the TGA's rescheduling decision.

MMA also strongly supports ongoing and new research into the use of psychedelic medicines as part of mental health treatments. MMA is already funding or part funding four different trials. The announcement by the Commonwealth Government of a \$15 million grant round to support psychedelic medicine research (the largest government grant round for this purpose anywhere in the World) was the direct result of MMA's representations and advocacy.

To further broaden the research base in Australia, MMA is delighted to announce that it will consider applications from research organisations to supply GMP medical grade psilocybin and GMP medical grade MDMA at no cost to support new clinical trials. MMA is particularly interested in supporting clinical trials that extend knowledge of how to optimise treatment results and/or extend the application of these medicinal therapies to other classes of mental and physical illnesses.

The Chairman of MMA, Peter Hunt AM, said that: *"Since the establishment of Mind Medicine Australia 4 years ago, Australia has moved from starting its first clinical trial of psychedelic*



MIND MEDICINE
A U S T R A L I A

medicine to multiple trials and has become the first country in the World to reschedule these substances for clinical use as medicines. We have moved from being largely absent from this area of medical innovation to fast becoming a World leader. Given the high calibre of researchers in this country and the desperate need for new and more effective treatments, we are delighted to announce that we will consider applications from research organisations for the provision of medical grade GMP psilocybin and GMP medical grade MDMA at no cost to support new innovative trials."

For further information please contact:

- **For media inquiries:**

Please contact Peter Hunt AM, Chair, Mind Medicine Australia
peter@mindmedicineaustralia.org, 0419 271 483

- **For inquiries from research organisations seeking access to these medicines:**

Please contact Scott Edwards, scott@mindmedicineaustralia.org, 0408 300 793 or
Ilan Hayman, ilan@mindmedicineaustralia.org, 0402 749 997